

DAFTAR PUSTAKA

1. Soellistidjo SA, Hermina N, Achmad R, et al. *Konsensus Pengelolaan dan Pencegahan Diabetes Melitus tipe 2 di Indonesia*. 2015. Perkeni..
2. Fong DS, Aiello L, Gardner TW. *Retinopathy in Diabetes*. *Diab Care*. 2004; 27: S84-S87
3. Pandelaki Karel. Retinopati Diabetik . In: Sudoyo AW, Setiyohadi, et al. *Buku Ajar Ilmu Penyakit Dalam jilid II*. Jakarta, Indonesia: Interna Publishing. 2014: 2400-7.
4. Cai J, Boulton M. *The pathogenesis of diabetic retinopathy: old concepts and new questions*. *Eye (Lond)*. 2002; 16(3): 242–60.
5. Smith LE, Shen W, Perruzzi C, et al. *Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor*. *Nat Med*. 1999 ; 5 (12):1390–5.
6. Tang J, Kern TS. Inflammation in diabetic retinopathy. *Prog Retin Eye Res*. 2011 Sep;30(5):343-58
7. Jonston, R. *An overview of the innate immune system*. https://www.uptodate.com/contents/an-overview-of-the-innate-immune-system?search=neutrophil&source=search_result&selectedTitle=3~150&u sage_type=default&display_rank=3. (Accessed on Septmber 05, 2019).
8. Larosa, D., Orange, J. *Lymphocytes*. *Journal of Allergy and Clinical Immunology*. (2008). 121(2), S364–S369.
9. Huang, L , Xie, Y, Dai, S et.al. *Neutrophil-to-lymphocyte ratio in diabetic microangiopathy*. 2016
10. Latief A. *Evaluasi Rasio Neutrofil-Limfosit pada Penderita Diabetes Melitus Tipe 2 dengan Retinopati Diabetik*. <http://etd.repository.ugm.ac.id/downloadfile/157676/potongan/S1-2018365578-abstract.pdf> (Accessed on Septmber 05, 2019).

11. Ulu SM, Dogan M, Ahsen A, et al. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. *Diabetes Technol Ther.* 2013 Nov;15(11):942-7
12. Çağrı İlhan, Mehmet Çıtırık, Mehmet Murat Uzel, Kemal Tekin. The Optimal Cutoff Value of Neutrophil/Lymphocyte Ratio for Severe Grades of Diabetic Retinopathy. *Beyoglu Eye J.* 2019; 4(2): 76-81
13. Chey EY. *Pathophysiology of Diabetic Retinopathy In : Le Roith D et al, editor. Diabetes Melitus a Fundamental and Clinical text, 3rd edition. Philadelphia : Lippincolt William & Wilkins, 2004 : 1304-1311*
14. Tarr JM, Kirt K, Mohil C, et al. *Pathophysiology of Diabetic Retinopathy. ISRN Ophtamol .2012 ; (12) : 1-13.*
15. Chittawar S, Dutta D, Qureshi Z, Surana V, Khandare S, Dubey TN. *Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in Indians with type-2 diabetes. Indian J Endocr Metab.* 2017.
16. UK Prospective Diabetes Study (UKPDS) Group. *Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet .1998 ; (352) : 837–53.*
17. Writing Team for Diabetes Control and Complications Trial/Epidemiology of Diabetic Interventions and Complications Research Group. *Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA.* 2002 ; (287) : 2563–9.
18. UK Prospective Diabetes Study Group. *Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ.* 1998 ; (317) : 703–13.
19. Marlina T, Tamara P, Ivana PR, et al. *Obesity a risk factor for microvascular and neuropathic complications in diabetes. Diabetologica.* 2003; 32 (2) : 72-79.

20. Kautzky-Willer A, Harreiter J, Pacini G et al. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev.* 2016 Jun;37(3):278-316
21. Cho NH, Kim TH, Woo SJ, et al. Optimal HbA1c cutoff for detecting diabetic retinopathy. *Acta Diabetol.* 2013 Dec;50(6):837-42
22. Ghasemi Falavarjani K, Nguyen Q. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. *Eye.* 2013;27(7):787-794.
23. Liu L, Quang ND, Banu R, Kumar H, Tham YC, et al. Hypertension, blood pressure control and diabetic retinopathy in a large population-based study. 2020.PLOS ONE 15(3)
24. Gillow JT, Gibson JM, Dodson PM. Hypertension and diabetic retinopathy—what’s the story?. *British Journal of Ophthalmology* 1999;**83**:1083-1087
25. Grunwald JE, Brucker AJ, Schwartz SS, et al. Diabetic glycaemic control and retinal blood flow.1990. *Diabetes.* 39:602–607.
26. Kohner EM Diabetic retinopathy.1993. *BMJ* 307:1195–1199
27. Schmid-Schönbein GW, Seiffge D, DeLano FA, et al. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. *Hypertension.* 1991;17:323-330
28. Davies MJ, Cordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selection in human atherosclerosis. *J Pathol.* 1993;171:223-229
29. Namperumalsamy P, Kim R, Vignesh TP, et al. Prevalence and risk factors for diabetic retinopathy: a population-based assessment from Theni district, South India. *Br J Ophthalmol* 2009;93;429e34.
30. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia* 2001;44:156e63.

31. Klein R, Klein EK, DeMets DL, et al. The Wisconsin Epidemiologic Study of diabetic retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Arch Ophthalmol* 1984;102:527e32.
32. Klein R, Klein EK, Cruickshanks KJ, et al. The Wisconsin Epidemiologic Study of diabetic retinopathy XIV. Ten-year incidence and progression of diabetic retinopathy. *Arch Ophthalmol* 1994;112:1217e28.
33. Lim CC, Lee SY, Cheng CL, et al. Diabetic retinopathy in diabetics referred to a tertiary centre from a nationwide screening programme. *Ann Acad Med Singapore* 2008;37:753e9.



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.





Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 589/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 23 September 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20070332	No Sponsor Protokol	
Peneliti Utama	dr. Idrus	Sponsor	
Judul Peneliti	PERBANDINGAN RASIO NEUTROFIL LIMFOSIT PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN RETINOPATI DIABETIK TIPE PROLIFERATIF DAN NON PROLIFERATIF		
No Versi Protokol	1	Tanggal Versi	30 Juli 2020
No Versi PSP	1	Tanggal Versi	30 Juli 2020
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo dan RS Jejaring, Laboratorium Prodia di Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 23 September 2020 sampai 23 September 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan